Mary DiBiase - Sep 8, 2021 Form 3 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role: Chief Operating Officer
Signature: /s/ Derek M. Meisner, attorney-in-fact
Stock symbol: XFOR
Transactions as of: Sep 8, 2021
Transactions value $: $0
Form type: 3
Date filed: 9/10/2021, 04:08 PM
Next filing: Feb 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	XFOR	Common Stock						64.5K	Sep 8, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XFOR	Stock Option (right to buy)							Sep 8, 2021	Common Stock	15.2K	$6.84	Direct	F2
holding	XFOR	Stock Option (right to buy)							Sep 8, 2021	Common Stock	1.9K	$7.08	Direct	F3
holding	XFOR	Stock Option (right to buy)							Sep 8, 2021	Common Stock	10.1K	$10.44	Direct	F4
holding	XFOR	Stock Option (right to buy)							Sep 8, 2021	Common Stock	9.47K	$14.75	Direct	F5
holding	XFOR	Stock Option (right to buy)							Sep 8, 2021	Common Stock	22.5K	$10.00	Direct	F6
holding	XFOR	Stock Option (right to buy)							Sep 8, 2021	Common Stock	7.5K	$8.69	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 58,293 shares underlying restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. Of the total shares underlying outstanding restricted stock units, (a) 2,916 shares will vest on June 15, 2022; 2,917 shares will vest on June 23, 2022; 5,834 shares will vest on August 17, 2022; 2,916 shares will vest on June 15, 2023 and 2,917 shares will vest on June 23, 2023 (b) 3,156 shares will vest in two equal instalments on June 30, 2022 and June 30, 2023 and (c) 37,637 shares will vest in three equal instalments on February 11, 2022, February 11, 2023 and February 11, 2024, in each case subject to the Reporting Person providing continuous service to the Issuer on such dates.
F2	Fully vested as of July 12, 2021.
F3	Fully vested as of April 11, 2020.
F4	Twenty five percent (25%) of the shares underlying the option vested on August 22, 2019 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.
F5	Twenty five percent (25%) of the shares underlying the option vested on June 17, 2020 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.
F6	Twenty five percent (25%) of the shares underlying the option vested on February 10, 2021 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.
F7	Twenty five percent (25%) of the shares underlying the option vested on June 10, 2021 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.